Oxford Secures £118M for AI Vaccine Research
Here’s a summary of the provided text, focusing on the key information:
Oxford Launches £118m AI Vaccine Research Program (CoI-AI)
The University of Oxford, in partnership with the Ellison Institute of Technology (EIT), has launched a £118 million research programme called CoI-AI (Correlates of Immunity-Artificial Intelligence). The program aims to combat antibiotic resistance by developing new vaccines through a combination of:
Human Challenge Trials: Volunteers are safely exposed to bacteria (like Streptococcus pneumoniae, Staphylococcus aureus, and E. coli) under controlled conditions.
Artificial Intelligence (AI): EIT will provide its AI technology to analyze immune responses and identify what protects against infection.
Immunology Expertise: Leveraging Oxford’s established expertise in immune science and vaccine development.
Key Goals & features:
Focus: Understanding how the immune system responds to bacteria causing serious infections and contributing to antibiotic resistance.
Established: December 2024
EIT’s Role: Provides AI technology, computing power (via Oracle), and a Scholars program to support emerging scientists.
Leadership: Led by the Oxford Vaccine Group, with Professor Sir andrew Pollard as Director.
Impact: aims to develop solutions and future leaders to address global health challenges.